Skip to search formSkip to main contentSkip to account menu

continuous erythropoietin receptor activator

Known as: CERA (erythropoietin receptor activator) 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (2)

ErythropoietinPolyethylene Glycols
Methoxy polyethylene glycol-epoetin betaRo 50-3821

Narrower (1)

Mircera

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Anemia Treatment by Erythropoiesis-stimulating Agents during the 6 Months before the Initiation of Hemodialysis: Comparison of Darbepoetin Alfa and Continuous Erythropoietin Receptor Activator.
Anemia in chronic kidney disease (CKD) is a risk factor for cardiovascular diseases and is treated by long-acting erythropoiesis… 
2016
2016
Impact of Continuous Erythropoietin Receptor Activator on Selected Biomarkers of Cardiovascular Disease and Left Ventricle Structure and Function in Chronic Kidney Disease
Background. Cardiovascular morbidity and mortality are very high in patients with chronic kidney disease (CKD). The purpose of… 
2015
2015
Randomized Controlled Trial of Darbepoetin α Versus Continuous Erythropoietin Receptor Activator Injected Subcutaneously Once Every Four Weeks in Patients with Chronic Kidney Disease at the Pre…
Continuous erythropoietin receptor activator (CERA) seems to maintain a stable hemoglobin (Hb) level because its half-life is… 
2015
2015
Effects of Long‐Term Erythropoiesis‐Stimulating Agents on Iron Metabolism in Patients on Hemodialysis
Continuous erythropoietin receptor activator (CERA) and darbepoetin‐α (DA) might differently affect iron metabolism and… 
2012
2012
[The efficacy and safety of continuous erythropoietin receptor activator in dialytic patients with chronic renal anemia: an open, randomized, controlled, multi-center trial].
OBJECTIVE To evaluate the efficacy and safety of continuous erythropoietin receptor activator (C.E.R.A.) once every 4 weeks by… 
2010
2010
Biaxial flexural strength of Turkom-Cera core compared to two other all-ceramic systems
Advances in all-ceramic systems have established predictable means of providing metal-free aesthetic and biocompatible materials… 
2008
2008
Erythropoietin Prevents Diabetes-Induced Podocyte Damage
Objective: Erythropoietin (EPO) has cytoprotective effects apart from its hematopoietic effects. We studied the effects of… 
2007
2007
Subcutaneous injection pain with C.E.R.A., a continuous erythropoietin receptor activator, compared with darbepoetin alfa
ABSTRACT Objective: This study assessed injection site pain following subcutaneous (SC) administration with a continuous… 
Review
2007
Review
2007
The latest advances in kidney diseases and related disorders.
The 39th Annual Meeting of the American Society of Nephrology was held in San Diego, California, U.S.A., November 16-19, 2006… 
1991
1991
Matrix vesicle enzyme activity in endosteal bone following implantation of bonding and non-bonding implant materials.
The effect of bone bonding (KGy-Cera) and non-bone bonding (KGy-213) implant materials on primary mineralization was examined in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)